Valence Discovery

Valence Discovery, formerly known as InVivo AI, is a Canadian AI-driven drug discovery company focused on designing novel small-molecule chemistry against difficult biological targets. The company built machine-learning tools for molecular representation, de novo ligand design, few-shot learning, and multiparameter optimization to support hit discovery and lead optimization. Rather than advancing a broad disclosed therapeutic pipeline of its own, Valence primarily operated as a platform-oriented techbio company. It was acquired by Recursion Pharmaceuticals in May 2023 and appears to continue operating within Recursion as an acquired subsidiary or operating unit contributing digital chemistry capabilities.